文献速递皮肤肿瘤皮肤感染

伏立康唑与美国肺移植受者角质形成细胞癌风险

Voriconazole and the Risk of Keratinocyte Carcinomas Among Lung Transplant Recipients in the United States.
PubMed 文献 · JAMA Dermatol · 2020-01-01

这项基于美国国家移植受者科学登记系统的队列研究纳入9599例非西班牙裔白人肺移植受者,分析伏立康唑等抗真菌药与皮肤鳞状细胞癌(SCC)及基底细胞癌(BCC)风险的关系。结果显示伏立康唑使用与SCC风险增加相关,且随暴露时间延长风险升高;伊曲康唑与SCC和BCC风险增加均相关,泊沙康唑与BCC风险增加相关。

要点

  • 伏立康唑使用超过15个月者SCC风险显著增加(AHR 3.05)。
  • 伊曲康唑暴露与SCC风险增加相关(AHR 1.20)。
  • 伊曲康唑和泊沙康唑与BCC风险增加相关。

核心结论

  • 伏立康唑使用与肺移植受者SCC风险增加相关,尤其在长期暴露后。
  • 伊曲康唑暴露与SCC和BCC风险增加均相关,泊沙康唑与BCC风险增加相关。

研究设计与样本

  • 抗真菌药物暴露从药房索赔数据获取,作为每30天评估的时间变化暴露,累积暴露按月计算。

主要发现

  • 与无伏立康唑使用相比,使用1-3个月SCC的AHR为1.09(95%CI 0.90-1.31),4-7个月为1.42(95%CI 1.16-1.73),8-15个月为2.04(95%CI 1.67-2.50),超过15个月为3.05(95%CI 2.37-3.91)。
  • 曾使用伊曲康唑与SCC风险增加相关(AHR 1.20,95%CI 1.00-1.45)。
  • BCC风险与伏立康唑使用无关,但与伊曲康唑使用(AHR 1.74,95%CI 1.27-2.37)或泊沙康唑使用(AHR 1.55,95%CI 1.00-2.41)相关。

关键数值与推荐

  • 伏立康唑使用1-3个月SCC的AHR 1.09(95%CI 0.90-1.31),4-7个月1.42(95%CI 1.16-1.73),8-15个月2.04(95%CI 1.67-2.50),超过15个月3.05(95%CI 2.37-3.91)。
  • 伊曲康唑暴露SCC的AHR 1.20(95%CI 1.00-1.45),BCC的AHR 1.74(95%CI 1.27-2.37)。
  • 泊沙康唑暴露BCC的AHR 1.55(95%CI 1.00-2.41)。

临床怎么用

  • 对肺移植受者,尤其SCC高风险者,应评估伏立康唑长期使用的风险-获益比,考虑缩短疗程或替代药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The antifungal medication voriconazole is used to prevent and treat aspergillosis, a major cause of mortality among recipients of lung transplants (hereinafter referred to as lung recipients). Small studies suggest that voriconazole increases risk of cutaneous squamous cell carcinoma (SCC). OBJECTIVE: To examine associations of voriconazole and other antifungal medications with risk of keratinocyte carcinomas (SCC and cutaneous basal cell carcinoma [BCC]) in lung recipients. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study included non-Hispanic white patients (n = 9599) who underwent lung transplant in the United States from January 1, 2007, to December 31, 2016, identified through the national Scientific Registry of Transplant Recipients with data linkable to pharmacy claims. Data were analyzed from March 1, 2018, to February 13, 2019. EXPOSURES: Antifungal medication use, including voriconazole, itraconazole, posaconazole, and other antifungals, was ascertained from pharmacy claims and treated as a time-varying exposure (assessed every 30 days). Cumulative antifungal exposure was calculated as the total number of exposed months. MAIN OUTCOMES AND MEASURES: Primary outcomes were the first SCC or BCC reported to the transplant registry by transplant centers. Follow-up began at transplant and ended at SCC or BCC diagnosis, transplant failure or retransplant, death, loss to follow-up, or December 31, 2016. Cox proportional hazards regression models were used to estimate adjusted hazard ratios (AHRs) for each antifungal medication. RESULTS: Among the 9793 lung transplants in 9599 recipients included in the analysis, median age at transplant was 59 (interquartile range [IQR], 48-65) years, 5824 (59.5%) were male, and 5721 (58.4%) reported ever smoking. During a median follow-up of 3.0 (IQR, 1.4-5.0) years after transplant, 1031 SCCs (incidence, 322 per 10 000 person-years) and 347 BCCs (incidence, 101 per 10 000 person-years) were reported. Compared with lung recipients with no observed voriconazole use, those with 1 to 3 months of voriconazole use experienced increased AHR for SCC of 1.09 (95% CI, 0.90-1.31); 4 to 7 months, 1.42 (95% CI, 1.16-1.73); 8 to 15 months, 2.04 (95% CI, 1.67-2.50); and more than 15 months, 3.05 (95% CI, 2.37-3.91). Ever itraconazole exposure was associated with increased SCC risk (AHR, 1.20; 95% CI, 1.00-1.45). For BCC, risk was not associated with voriconazole use but was increased with itraconazole use (AHR, 1.74; 95% CI, 1.27-2.37) or posaconazole use (AHR, 1.55; 95% CI, 1.00-2.41). CONCLUSIONS AND RELEVANCE: In this study, voriconazole use was associated with increased SCC risk among lung recipients, especially after prolonged exposure. Further research evaluating the risk-benefit ratio of shorter courses or alternative medications in transplant recipients at high risk for SCC should be considered.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. D'Arcy ME, Pfeiffer RM, Rivera DR, et al. Voriconazole and the Risk of Keratinocyte Carcinomas Among Lung Transplant Recipients in the United States. JAMA Dermatol. 2020. PMID: 32401271. doi:10.1001/jamadermatol.2020.1141

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。